+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bone Cancer Drugs Market, by Type, by Treatment Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

  • PDF Icon

    Report

  • 212 Pages
  • August 2021
  • Region: Global
  • Coherent Market Insights Pvt Ltd.
  • ID: 5417342
Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. The market of bone cancer is segmented on the basis of types of bone cancer, such as, primary bone cancer and secondary bone cancer. Primary bone cancer is the type of cancer that originates from rapid and uncontrollable growth of the bone and related tissues. Whereas, Secondary bone cancer is when a cancer that started somewhere else in the body has spread to the bones. The bone cancer is also classified as, osteosarcoma, ewing’s sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and admantinomas.



Market Dynamics


The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2020, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA’s Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.

Key features of the study:

  • This report provides in-depth analysis of the global bone cancer drug market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bone cancer drug market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd, and Teva Pharmaceutical
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global bone cancer drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drug market

Detailed Segmentation:


Global Bone Cancer Drug Market, By Type:

  • Multiple Myeloma
  • Osteosarcoma
  • Chondrosarcoma
  • Ewing’s Sarcoma

Global Bone Cancer Drug Market, By Treatment Type:

  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Surgery

Global Bone Cancer Drug Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Bone Cancer Drug Market, By Region:

  • North America
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Region/Country
  • South Africa
  • Central Africa
  • North Africa

Company Profiles

  • Advaxis, Inc.
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Cellectar Biosciences, Inc.
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Debiopharm Group
  • Merck & Co
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical
“*” marked represents similar segmentation in other categories in the respective section.
Frequently Asked Questions about the Bone Cancer Drugs Market

What is the estimated value of the Bone Cancer Drugs Market?

The Bone Cancer Drugs Market was estimated to be valued at $1170.5 Million in 2021.

What is the growth rate of the Bone Cancer Drugs Market?

The growth rate of the Bone Cancer Drugs Market is 4.2%, with an estimated value of $1564 Million by 2028.

What is the forecasted size of the Bone Cancer Drugs Market?

The Bone Cancer Drugs Market is estimated to be worth $1564 Million by 2028.

Who are the key companies in the Bone Cancer Drugs Market?

Key companies in the Bone Cancer Drugs Market include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group and Bayer AG.

Table of Contents

1. Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Treatment Type
  • Market Snapshot, Distribution Channel
  • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis
  • Market Dynamics
  • Drivers
  • Restraints
  • Opportunity
  • Impact Analysis
  • Pipeline Analysis
  • Regulatory Scenario
  • Market Trends
  • Key Developments
  • Epidemiology
  • PEST Analysis
  • Brand Analysis

4. Global Bone Cancer Drug Market- Impact of Coronavirus (COVID-19) Pandemic
  • Economic Impact
  • Impact on Clinical Trials and Drug Development
  • Government Initiatives

5. Global Bone Cancer Drug Market, By Type, 2017 - 2028, (US$ Mn)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
  • Multiple Myeloma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Osteosarcoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Chondrosarcoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Ewing’s Sarcoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Bone Cancer Drug Market, By Treatment Type, 2017 - 2028, (US$ Mn)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
  • Targeted Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Chemotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Radiation Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Surgery
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Bone Cancer Drug Market, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
  • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Bone Cancer Drug Market, By Region, 2017 - 2028, (US$ Mn)
  • Introduction
  • Market Share Analysis, By Region, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2028
  • Regional Trends
  • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 - 2028, (US$ Mn)
  • U.S.
  • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 - 2028, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 - 2028, (US$ Mn)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 - 2028, (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017 - 2028, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2028, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Region/Countries, 2017 - 2028, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape
  • Heat Map Analysis
  • Market Share Analysis
  • Advaxis, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Cellectar Biosciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • OPKO Health, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Debiopharm Group
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Merck & Co
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Takeda Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • F. Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Teva Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies

- Analyst Views
10. Section
  • Research Methodology
  • About us

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Advaxis, Inc.
  • Cellectar Biosciences, Inc.
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Debiopharm Group
  • Merck & Co
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical